多发性骨髓瘤患者血清LDH β2-MG水平测定的临床意义

目的：探讨分析多发性骨髓瘤患者血清LDH和β2-MG水平测定的临床意义。方法多发性骨髓瘤患者25例，健康体检者20例，检测并比较两组血清乳酸脱氢酶（LDH）和血清β2微球蛋白（β2-MG）水平。结果与对照组比较，多发性骨髓瘤Ⅰ期、Ⅱ期、Ⅲ期患者的血清LDH和β2-MG水平明显高于对照组，其中骨髓瘤Ⅲ期患者的β2-MG水平、血清LDH水平明显高于骨髓瘤Ⅰ期、Ⅱ期；骨髓瘤组治疗期间的血清LDH和β2-MG水平比较中，部分缓解组、有效组与无效组比较，差异有统计学意义（P〈0.05）。结论血清LDH和β2-MG水平检测为多发性骨髓瘤患者的病理分期、预后判断等提供重要的参考价值，可以作为临床诊断评估的辅助指标。

ObjectiveTo investigate the clinical significance of determination of multiple myeloma patients serum LDH and beta 2-MG level.Methods25 cases of multiple myeloma patients,20 healthy subjects,and detection of serum lactic acid were compared between the two groups（LDH）dehydrogenase and serum beta 2 microglobulin（beta 2-MG）results and level. Compared to the control group,multiple myeloma stage Ⅰ,Ⅱ,Ⅲ patients with serum LDH and beta 2-MG level was significantly higher than the control group,the bone marrow of patients with tumor stage Ⅲ beta 2-MG level,serum LDH level was significantly higher than that of myeloma stage I,II;during the myeloma group serum LDH and the level of 3 2-MG,partial remission group group,effective group and ineffective,the difference was statistically significant（P〈0.05）.ConclusionsThe detection of serum LDH and beta 2-MG level in patients is valuable for clinical diagnosis, stagingand prognosis prediction for multiple myeloma.